Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults

Vaccine

Volumn 23, Issue 1, 2004, Pages 29-35

  Beeching, Nicholas J ^a   Clarke, Paul D ^b   E Kitchin, Nicholas R ^c   Pirmohamed, Jackie ^d   Veitch, Keith ^e   Weber, Françoise ^e  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b MASTA Travel Health Centre   (United Kingdom)

^c Aventis Pasteur MSD   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e SANOFI PASTEUR   (France)

Author keywords

Combined vaccine; Hepatitis A; Typhoid

Indexed keywords

ANTIBODY; HEPATITIS A VACCINE; HEPATYRIX; HYPATRIX; INACTIVATED VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIATIM;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; GINGIVITIS; HEADACHE; HEARTBURN; HEMATOMA; HEPATITIS A; HUMAN; IMMUNE RESPONSE; LARYNX DISORDER; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; TYPHOID FEVER; VACCINATION REACTION; VOMITING;

ADOLESCENT; ADULT; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, COMBINED;

EID: 7444264760     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.05.040     Document Type: Article

References (25)

1. R. Steffen, and H.L. DuPont Manual of travel medicine and health 1999 BC Decker Inc. Canada
2. G. De Serres, B. Duval, R. Shadmani, N. Boulianne, G. Pohani, and M. Naus Ineffectiveness of the current strategy to prevent hepatitis A in travellers J. Travel Med. 9 2002 10 16
3. R. Steffen Despite good tools, we do not effectively reduce travelers' hepatitis A J Travel Med. 9 2002 1 2
4. J. Beran, M. Beutels, K. Levie, P. Van Damme, I. Dieussaert, and M. Gillet A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity J Travel Med. 7 2000 246 252
5. Aventis Pasteur, unpublished observations.
6. C.O. Tacket, C. Ferreccio, and J.B. Robbins Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines J. Infect. Dis. 154 1986 342 345
7. R.G. Newcombe Interval estimation for the difference between independent proportions: comparison of eleven methods Stat. Med. 17 1998 873 890
8. K.P. Klugman, H.J. Koornhof, J.B. Robbins, and N.N. Le Cam Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization Vaccine 14 1996 435 438
9. J.H. Mermin, J.M. Townes, M. Gerber, N. Dolan, E.D. Mintz, and R.V. Tauxe Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance Arch. Int. Med. 158 1998 633 638
10. R. Steffen Risk of hepatitis A in travellers Vaccine 10 Suppl 1 1992 S69 S72
11. E. Vidor, C. Ratheau, P. Briantais, and D. Vuillier Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim™) J. Travel Med. 5 1998 167 172
12. C.Y. Lee, L.M. Huang, P.I. Lee, H.H. Chiu, R. Dumas, and B. Milcamps Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children Southeast Asian J Trop Med Public Health 31 2000 29 36
13. R. Dumas, R. Forrat, J. Lang, T. Farinelli, and L. Loutan Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + Yellow Fever vaccine Adv. Ther. 14 1997 160 167
14. J.N. Zuckerman The importance of injecting vaccines into muscles BMJ 321 2000 1237 1238
15. L. Hessel, H. Debois, M. Fletcher, and R. Dumas Experience with Salmonella typhi Vi capsular polysaccharide vaccine Eur. J. Clin. Microbiol. Infect. Dis. 18 1999 609 620
16. S.A. Plotkin, and N. Bouveret-Le Cam A new typhoid vaccine composed of the Vi capsular polysaccharide Arch. Int. Med. 155 1995 2293 2299
17. C. Van Hoecke, E. Lebacq, J. Beran, R. Prymula, and F. Collard Concomitant vaccination against hepatitis A and typhoid fever J. Travel Med. 5 1998 112 120
18. E. Vidor, C. Xueref, C. Blondeau, A. Bajard, A. Francon, and A. Goudeau Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine Biologicals 24 1996 235 242
19. E. Lebacq Comparative tolerability and immunogenicity of Typherix or Typhim Vi in healthy adults: 0, 12-month and 0, 24-month administration Biodrugs 15 Suppl 1 2001 5 12
20. J. Zuckerman, F. Peyron, M. Wallon, F. Gay, H. Delolme, and P. Briantais Comparison of the safety and immunogenicity of two inactivated hepatitis A vaccines Adv Ther. 14 1997 116 124
21. J.N. Zuckerman, C.T. Kirkpatrick, and M. Huang Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A J Travel Med. 5 1998 18 22
22. G. Wiedermann, M. Kundi, and F. Ambrosch Estimated persistence of anti-HAV antibodies after single dose and booster dose hepatitis A vaccination (0-6 schedule) Acta Trop 69 1998 121 125
23. P. Van Damme, J. Banatvala, O. Fay, S. Iwarson, B. McMahon, and K. Van Herck Hepatitis A booster vaccination: is there a need? Lancet 362 2003 1065 1071
24. D.S. Krause Hepatitis A vaccine and travel departure (letter) Clin. Infect. Dis. 26 1998 1018
25. G. Webster, E. Barnes, G. Dusheiko, and I. Franklin Protecting travelers from hepatitis A BMJ 322 2001 194 195